Latanoprostene bunod (LBN) 0.024%, a newly approved glaucoma eye drop, is metabolized into latanoprost acid and a nitric oxide (NO)-donating moiety, thus increasing the outflow of aqueous humor through the uveoscleral and trabecular routes, respectively. This study aimed to evaluate the intraocular pressure (IOP)-lowering effect of LBN among patients with open-angle glaucoma (OAG) and ocular hypertension (OHT). The effectiveness of LBN was also compared with timolol maleate 0.5% and latanoprost 0.005%. We searched PubMed and Embase between 1 January 2010, and 31 March 2022 and adopted only peer-reviewed clinical studies in our meta-analysis. A total of nine studies (2389 patients with OAG or OHT) assessing the IOP-reduction effect of LBN were included. Standardized mean differences (SMDs) of IOP between post-treatment time points (2 weeks, 6 weeks, 3 months, 6 months, 9 months, and 12 months) and baseline were calculated. The pooled analysis according to each time point revealed a significant IOP drop after LBN treatment (all p values for SMD < 0.05). In addition, LBN revealed a significantly stronger efficacy in decreasing IOP than timolol maleate 0.5% and latanoprost 0.005% during the follow-up period of three months. No serious side effects of LBN 0.024% were reported. Our study concluded that LBN could achieve good performance for IOP reduction in patients with OAG and OHT. The safety was favorable with no severe side effects.

中文翻译：

---

Latanoprostene Bunod 0.024% 治疗开角型青光眼和高眼压症：一项荟萃分析

Latanoprostene bunod (LBN) 0.024%，一种新批准的青光眼滴眼液，被代谢为拉坦前列素酸和一氧化氮 (NO) 供体部分，从而分别通过葡萄膜巩膜和小梁途径增加房水的流出。本研究旨在评估 LBN 对开角型青光眼 (OAG) 和高眼压症 (OHT) 患者的眼压 (IOP) 降低效果。还将 LBN 的有效性与马来酸噻吗洛尔 0.5% 和拉坦前列素 0.005% 进行了比较。我们在 2010 年 1 月 1 日至 2022 年 3 月 31 日期间搜索了 PubMed 和 Embase，并且在我们的荟萃分析中仅采用了同行评审的临床研究。共有九项研究（2389 名患有 OAG 或 OHT 的患者）评估了 LBN 的 IOP 降低效果。治疗后时间点（2 周、6 周、计算 3 个月、6 个月、9 个月和 12 个月）和基线。根据每个时间点的汇总分析显示 LBN 治疗后 IOP 显着下降（所有SMD 的p值 < 0.05)。此外，在三个月的随访期间，LBN 显示在降低 IOP 方面的功效明显强于马来酸噻吗洛尔 0.5% 和拉坦前列素 0.005%。没有报告 LBN 0.024% 的严重副作用。我们的研究得出结论，LBN 可以在降低 OAG 和 OHT 患者的眼压方面取得良好的效果。安全性良好，无严重副作用。